|
PSPH expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.72929465086713E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.90440030201478E-10 |
| Normal-vs-Stage2 |
3.151000E-01 |
| Normal-vs-Stage3 |
4.2049030923863E-11 |
| Normal-vs-Stage4 |
1.63169477929159E-12 |
| Stage1-vs-Stage2 |
2.176400E-02 |
| Stage1-vs-Stage3 |
4.409900E-02 |
| Stage1-vs-Stage4 |
8.41270000000449E-05 |
| Stage2-vs-Stage3 |
2.099100E-03 |
| Stage2-vs-Stage4 |
6.03099999999523E-05 |
| Stage3-vs-Stage4 |
9.003800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.70758979073571E-12 |
| Normal-vs-AfricanAmerican |
5.041300E-03 |
| Normal-vs-Asian |
6.69940000141978E-08 |
| Caucasian-vs-AfricanAmerican |
3.367800E-01 |
| Caucasian-vs-Asian |
2.330000E-01 |
| AfricanAmerican-vs-Asian |
7.140600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.28159960211383E-10 |
| Normal-vs-Female |
1.6333001617852E-10 |
| Male-vs-Female |
6.093000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.14419634562091E-11 |
| Normal-vs-Age(41-60Yrs) |
2.60580002020561E-09 |
| Normal-vs-Age(61-80Yrs) |
3.79289999999921E-05 |
| Normal-vs-Age(81-100Yrs) |
2.365200E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.110200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.951800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.763400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.465200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.005200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.740400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.25499985140721E-10 |
| Classical-VS-Follicular |
1.66430000003714E-06 |
| Classical-VS-Other |
3.498800E-01 |
| Classical-VS-Normal |
3.5784708529718E-12 |
| Tall-VS-Follicular |
1.63768998362457E-12 |
| Tall-VS-Other |
7.111800E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.922800E-01 |
| Follicular-VS-Normal |
3.882400E-01 |
| Other-VS-Normal |
2.461800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.66245999999592E-05 |
| Normal-vs-N1 |
1.77635683940025E-14 |
| N0-vs-N1 |
4.89970000017159E-07 |
|
|
